在Olea europaea亚种的抗莱什曼活动. 拉佩里尼提取物是拉佩里尼的提取物
Souad Lahcene1, Lamia Trabelsi2, Mounir M Salem-Bekhit3
1Laboratory of Analytical Biochemistry and Biotechnology (LABAB), Faculty of Biological Sciences and Agronomic Sciences. Mouloud Mammeri University, Tizi-Ouzou, Algeria. souadlahcen@yahoo.fr.
Cellular and molecular biology (Noisy-le-Grand, France)
|June 10, 2023
概括
拉佩林橄树叶提取物显示对莱什曼尼亚婴儿有强大的抗莱什曼尼亚作用. 这种天然产品为目前的莱什曼病治疗提供了一个有希望的替代方案.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 寄生虫学的寄生虫学
背景情况:
- 莱什曼病是一种致命的公共卫生问题,治疗选择有限.
- 目前的莱什曼病治疗是昂贵的,长时间的,有副作用,并面临越来越多的寄生虫耐药性.
- 新的治疗策略至关重要,天然产品是研究重点.
研究的目的:
- 为了化学表征和量化拉佩林橄树 (Olea europaea亚种) 中的多. 拉佩里尼) 提取物. 提取物.
- 评估这些提取物对婴儿莱什马尼亚的抗莱什马尼亚活性.
- 为了确定具有潜在的leishmanicidal特性的特定生物活性化合物.
主要方法:
- 使用EAF和EAT溶剂从拉佩林橄树的叶子和果实中提取多.
- 使用光谱光度法量化总聚,黄和素的量化.
- 提取物的化学表征,以确定关键的生物分子.
- 在体外试验中测试了提取物对婴儿Leishmania.infantum的前性形式的疗效.
主要成果:
- 与水果提取物相比,橄叶提取物表现出高度的多,黄和素.
- 确定了关键的抗莱什曼化合物,如欧蛋白,氧醇,常规素,酸,咖啡酸,罗斯马林酸和奎尔丁.
- 叶子提取物表现出显著的莱什曼杀虫活性,致命剂量50 (LD50) 为7.52±2.71μl/ml,用于对抗莱什曼尼亚婴儿前列腺炎.
结论:
- 拉佩林橄树提取物,特别是从叶子中提取的,具有显著的体外抗莱什曼的活性.
- 鉴定到的多醇有助于观察到的莱什曼尼cidal 效应.
- 这些发现支持了Olea europaea亚种的潜力. 拉佩里尼作为利什曼病新疗法的来源.
更多相关视频
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.1K
06:57In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
8.3K
相关概念视频
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...